Institut Catala d'Oncologia, Hospital Duran i Reynals

L'Hospitalet de Llobregat 8908

0 studies enrolling now · 4 studies all time

What they study most

B-Cell Malignancies, CLL, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Relapsed/Refractory Follicular Lymphoma

Studies at this site

• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) — Stopped early